Furthermore, the L-DOPA treatment apparently increased L-DOPA-immunoreactivity in GFAP-positive striatal astrocytes on the lesioned side in hemi-PD rats (Figs. 2 and 3). This evidence concerns the gene GFAP and Parkinson disease.